Synergistic Killing of Staphylococcus aureus by Mefloquine and 18β-Glycyrrhetinic Acid

Infections caused by Staphylococcus aureus, specifically methicillin-resistant S. aureus (MRSA), pose a significant clinical challenge due to their inherent drug resistance. Drug repurposing which involves leveraging clinically approved agents with well-established safety profiles—offers a time- and cost-efficient strategy to bridge this therapeutic gap. This study investigates the synergistic antibacterial effects of the combination of 18β-glycyrrhetinic acid (18β-GA) and mefloquine hydrochloride (Mef) against MRSA, and elucidates the underlying molecular mechanisms of this combination. Our results revealed that the Mef+18β-GA combination effectively promotes anti-MRSA activity by disrupting biofilm integrity and suppressing the expression of key virulence genes, thereby significantly impairing both bacterial proliferation and pathogenicity. Transcriptomic analysis showed that the combination treatment globally modulated gene expression via downregulation of key virulence regulators (agr), adhesion-related genes (clfA, clfB, atl and fib), and antioxidant genes (katE, norB and msrB). We further validated the expression levels of clfA, sigB, katE and agrA by RT-qPCR. In a mouse skin infection model, the Mef+18β-GA combination mitigated skin lesions, reduced inflammatory cytokine levels (IL-1β and IL-6), and efficiently removed MRSA from local lesions and systemic organs. Collectively, these findings indicate that 18β-GA and mefloquine act synergistically against MRSA by targeting bacterial growth, biofilm maturation, antioxidant stress responses, and virulence gene expression. This study provides a promising, translationally relevant drug-repurposing combinatorial strategy for the clinical management of MRSA infections, offering the advantages of proven safety and rapid clinical translatability.

Authors

Institutions

Publication Details

Journal
Microorganisms
Published
2026-11-18
DOI
https://doi.org/10.3390/microorganisms14112677
Primary Topic
Antimicrobial Resistance in Staphylococcus
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Synergistic Killing of Staphylococcus aureus by Mefloquine and 18β-Glycyrrhetinic Acid

Huan Yang, Xinyu Chen, Junyu Chen, Lei Wan et al.
2 links
Microorganisms
Antimicrobial Resistance in Staphylococcus
article

Synergistic Killing of Staphylococcus aureus by Mefloquine and 18β-Glycyrrhetinic Acid

Huan Yang, Xinyu Chen, Junyu Chen, Lei Wan, Xuanyi Ren, Ruyi Huang, Xintong Jiang, Wenwen Cui, Xinxin Feng
article en

Abstract

Infections caused by Staphylococcus aureus, specifically methicillin-resistant S. aureus (MRSA), pose a significant clinical challenge due to their inherent drug resistance. Drug repurposing which involves leveraging clinically approved agents with well-established safety profiles—offers a time- and cost-efficient strategy to bridge this therapeutic gap. This study investigates the synergistic antibacterial effects of the combination of 18β-glycyrrhetinic acid (18β-GA) and mefloquine hydrochloride (Mef) against MRSA, and elucidates the underlying molecular mechanisms of this combination. Our results revealed that the Mef+18β-GA combination effectively promotes anti-MRSA activity by disrupting biofilm integrity and suppressing the expression of key virulence genes, thereby significantly impairing both bacterial proliferation and pathogenicity. Transcriptomic analysis showed that the combination treatment globally modulated gene expression via downregulation of key virulence regulators (agr), adhesion-related genes (clfA, clfB, atl and fib), and antioxidant genes (katE, norB and msrB). We further validated the expression levels of clfA, sigB, katE and agrA by RT-qPCR. In a mouse skin infection model, the Mef+18β-GA combination mitigated skin lesions, reduced inflammatory cytokine levels (IL-1β and IL-6), and efficiently removed MRSA from local lesions and systemic organs. Collectively, these findings indicate that 18β-GA and mefloquine act synergistically against MRSA by targeting bacterial growth, biofilm maturation, antioxidant stress responses, and virulence gene expression. This study provides a promising, translationally relevant drug-repurposing combinatorial strategy for the clinical management of MRSA infections, offering the advantages of proven safety and rapid clinical translatability.

MicroorganismsVol. 14(11)
Hunan University (CN), Xuzhou Medical College (CN), Liu Zhou Center for Disease Prevention and Control (CN), State Key Laboratory of Chemobiosensing and Chemometrics (CN)
National Natural Science Foundation of China, China Postdoctoral Science Foundation, Science and Technology Program of Hunan Province
Good health and well-being
Antimicrobial Resistance in Staphylococcus
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon